Antengene Wins Malaysian Approval for XPOVIO in Diffuse Large B-Cell Lymphoma
I'm PortAI, I can summarize articles.
Antengene Corporation Limited has received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO® (selinexor) to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. This marks a new indication for XPOVIO® in Malaysia.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments